The central role of CD40L signaling in generating pro-inflammatory responses makes it an attractive candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance, and neuroinflammation.
Tegoprubart (formerly known as AT-1501) is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. It was built around safety and engineered to maximize efficacy and half life.
Eledon Pharmaceuticals is building upon our deep understanding of the CD40/CD40L pathway, as well as preclinical, Phase 1 and Phase 2 data. We are concentrating on three therapeutic areas: transplantation focusing on kidney and islet cell transplantation, autoimmunity focusing on IgA Nephropathy, and neuro-degeneration focusing on amyotrophic lateral sclerosis (ALS).
We are dedicated to the highest ethical, humane and responsible treatment of animals necessary to the development of our medicines. We strive to replace the use of live animals, minimize the number of animals used, and refine our procedures to minimize distress, whenever scientifically possible and acceptable to regulators. We also work with our vendors to ensure their compliance with all applicable laws and regulations, as well as ethical best practices, related to animal-based research.